Ivermectin works as an antiviral against SARS-CoV-2 (COVID-19)

Update September 4, 2022- A new peer-reviewed study found that regular use of ivermectin reduced the risk of dying from COVID-19 by 92%.

Update August 31, 2022- The NIH added ivermectin to the list of drugs to treat COVID. The CDC page dates this as an April listing, but few seemed to have spotted this. By adding it to this NIH page for other drugs to treat COVID is a big deal.

First, ivermectin is now on a page with other “antivirals”. Simply admitting that is a milestone. Then, the NIH admits that the drug is “being evaluated”. The propagandists have wanted everyone to think this was drug to kill tapeworms in horses and had no antiviral activity.

It is too late now. The serious diseases is behind us. What a crime against humanity.

Update February 7, 2022- “Strictly regular use of ivermectin as prophylaxis for COVID-19 leads to a 90% reduction in COVID-19 mortality rate, in a dose-response manner: definitive results of a prospective observational”

Update January 31, 2022- TOKYO (Reuters) – Japanese trading and pharmaceuticals company Kowa Co Ltd (7807.T) on Monday said that anti-parasite drug ivermectin showed an “antiviral effect” against Omicron and other coronavirus variants in joint non-clinical research.

January 18, 2022- India, Mexico, and El Salvador distribute ivermectin to citizens in free COVID kits

August 11, 2021- Potential use of ivermectin for the treatment and prophylaxis of SARS-CoV-2 infection. Results: The reviewed literature suggests that there seems to be sufficient evidence about the safety of oral ivermectin, as well as the efficacy of the drug in the early-treatment and the prophylaxis of COVID-19. Conclusions: In the view of the available evidence, the Frontline COVID-19 Critical Care Alliance (FLCCC) recommends the use of oral ivermectin for both prophylaxis and early-treatment of COVID-19. Further well-designed studies should be conducted in order to explore the efficacy and safety of invermectin at low and high doses, following different dosing schedules, in both, the short and long-term treatment.

August 5, 2021- Prophylactic Role of Ivermectin in Severe Acute Respiratory Syndrome Coronavirus 2 Infection Among Healthcare Workers– Conclusion Two doses of oral ivermectin (300 μg/kg/dose given 72 hours apart) as chemoprophylaxis among HCWs reduced the risk of COVID-19 infection by 83% in the following month. Safe, effective, and low-cost chemoprophylaxis has relevance in the containment of pandemic alongside vaccine.

March 8, 2021- Treatment with Ivermectin Is Associated with Decreased Mortality in COVID-19 Patients: Analysis of a National Federated Database

February 16, 2021- Role of ivermectin in the prevention of SARS-CoV-2 infection among healthcare workers in India: A matched case-control study- Conclusion: Two-dose ivermectin prophylaxis at a dose of 300 μg/kg with a gap of 72 hours was associated with a 73% reduction of SARS-CoV-2 infection among healthcare workers for the following month. Chemoprophylaxis has relevance in the containment of pandemic.

Update March 4, 2023-

Update May 2, 2023-

  • Ivermectin works against COVID in double blind, randomized, controlled trial

Update May 3, 2023-

  • Australia’s TGA is Lifting the Ban on Ivermectin Effective June 1, 2023
This entry was posted in - Biotech, - Generics, - Pharma, FDA, Infectious disease. Bookmark the permalink.

Leave a Reply

Your email address will not be published. Required fields are marked *